Mark Sullivan Sells 11,276 Shares of Mind Medicine (MindMed) (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the sale, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mind Medicine (MindMed) Stock Down 3.8%

MNMD stock opened at $12.95 on Wednesday. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $14.43. The business’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $10.51. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $1.28 billion, a PE ratio of -6.35 and a beta of 2.57.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, research analysts anticipate that Mind Medicine will post -1.35 EPS for the current year.

Mind Medicine (MindMed) News Summary

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM‑120 moved into Phase III for GAD and MDD with pivotal readouts expected in 2026 — a clear near‑term clinical catalyst that supports upside expectations for the stock. Read More.
• Positive Sentiment: Broker and analyst enthusiasm (including recent buy/strong‑buy coverage and a handful of high targets) is lifting sentiment and provides potential support for the stock ahead of clinical readouts. Read More.
• Neutral Sentiment: Analyst/ownership mix is mixed: consensus ratings skew positive with an elevated average price target, while institutional ownership (~28%) gives market credibility but also means larger holders could add to volatility. Read More.
• Negative Sentiment: Clustered insider selling on Dec. 26 — CEO Robert Barrow (25,791 shares), Mark Sullivan (11,276 shares) and Daniel Karlin (5,600 shares) — has introduced immediate selling pressure and is the most direct reason cited for the stock trading down today. Read More.
• Negative Sentiment: Fundamental headwinds remain — recent quarterly results missed estimates and analysts model negative EPS for the year, which increases sensitivity to execution and clinical outcomes. Read More.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Institutional investors have recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in Mind Medicine (MindMed) during the first quarter worth approximately $1,556,000. Wellington Management Group LLP lifted its position in shares of Mind Medicine (MindMed) by 16.2% during the 1st quarter. Wellington Management Group LLP now owns 225,928 shares of the company’s stock valued at $1,322,000 after acquiring an additional 31,437 shares during the period. Rafferty Asset Management LLC acquired a new stake in shares of Mind Medicine (MindMed) during the 1st quarter worth $81,000. CreativeOne Wealth LLC acquired a new stake in shares of Mind Medicine (MindMed) during the 1st quarter worth $67,000. Finally, DRW Securities LLC bought a new position in shares of Mind Medicine (MindMed) in the first quarter worth $292,000. 27.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MNMD. Chardan Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Needham & Company LLC set a $28.00 price objective on Mind Medicine (MindMed) and gave the company a “buy” rating in a report on Monday, October 13th. Finally, Jones Trading initiated coverage on Mind Medicine (MindMed) in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mind Medicine (MindMed) currently has an average rating of “Buy” and an average price target of $30.33.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.